La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Aminoacide And NotTamae Ohye

List of bibliographic references

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
000917 Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
000952 Yoshiaki Furukawa [Canada]Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss
000959 Benoit Melchior [France] ; Véronique Nerriere-Daguin [France] ; David-A. Laplaud [France] ; Séverine Remy [France] ; Sandrine Wiertlewski [France] ; Isabelle Neveu [France] ; Philippe Naveilhan [France] ; Susan O. Meakin [Canada] ; Philippe Brachet [France]Ectopic expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent neuroprotection
000A83 A. Y. Alemdar [Canada] ; K. A. Baker [Canada] ; D. Sadi [Canada] ; V. C. Mcalister [Canada] ; I. Mendez [Canada]Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats
000C12 O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada]A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa
000D85 D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada]Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys
000E11 P. J. Blanchet [Canada] ; P. Allard [Canada] ; L. Gregoire [Canada] ; F. Tardif [Canada] ; P. J. Bedard [Canada]Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients
000E13 P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada]Remoxipride in the treatment of levodopa-induced psychosis
000E52 H. Kuwabara [Canada] ; P. Cumming ; Y. Yasuhara ; G. C. Leger ; M. Guttman ; M. Diksic ; A. C. Evans ; A. GjeddeRegional striatal DOPA transport and decarboxylase activity in Parkinson's disease
001021 D. B. Calne [Canada]Neurotoxins and degeneration in the central nervous system
001079 T. L. Perry ; C. Bergeron ; A. J. Biro ; S. Hansenβ-N-methylamino-L-alanine: chronic oral administration is not neurotoxic to mice
001125 T. L. Perry ; S. Hansen ; K. JonesBrain amino acids and glutathione in progressive supranuclear palsy

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022